Company Overview of X-BODY, Inc.
X-BODY, Inc. develops monoclonal antibody therapeutics. The company discovers and develops compounds against biologically relevant targets in oncology and ophthalmology. It also develops screening system that is applicable for various processes, such as generation of soluble VH domains, Fabs, IgGs, and bispecifics; selection against cell surface targets on live cells, including selections for function; affinity maturation; identification of stable VH-VL pairs; and epitope discovery by differential screening of live cells and other samples. X-BODY, Inc. was founded in 2008 and is based in Waltham, Massachusetts. As of June 1, 2015, X-BODY, Inc. operates as a subsidiary of Juno Therapeutics In...
100 Beaver Street
Waltham, MA 02453
Founded in 2008
Key Executives for X-BODY, Inc.
Co-Founder, President and Director
Senior Vice President of R&D
Compensation as of Fiscal Year 2015.
X-BODY, Inc. Key Developments
Kindred Biosciences and X-Body Biosciences Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health
Mar 31 14
Kindred Biosciences, Inc. and X-Body Biosciences jointly announced an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to Kindred Bio. X-Body will use its proprietary DNA-antibody technology and live cell functional selection technology to generate therapeutic antibodies and Kindred Bio will develop these antibodies to address unmet medical needs in companion animal health. X-Body's antibody technology is based on a method of linking an antibody to its gene, combined with a cell-free mammalian translational system, allowing rapid generation and screening of antibodies, as well as identification of bispecific antibodies. Its live cell selection technology can identify antibodies against membrane-bound targets.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 2, 2015
Most Searched Private Companies
Sponsored Financial Commentaries